Abstract:Growth signals, which typically originate from the surrounding microenvironment, are important for cells. However, when stimulation by growth factors becomes excessive and exceeds their threshold limit, deleterious effects may ensue. In patients with cancer, maintenance of tumors depends, at least in part, on growth factor stimulation, which can also facilitate cancer progression into advanced stages. This is particularly important when the tumor grows beyond its tissue boundaries or when it invades and colonizes other tissues. These aforementioned malignant events are known to be partly supported by elevated cytokine levels. Among the currently known growth signals, insulin-like growth factor (IGF)-1 and IL-6 have been previously studied for their roles in prostate cancer. Both IGF-1 and IL-6 have been reported to activate the RAPTOR independent companion of MTOR complex 2 (Rictor)/AKT/protein kinase C α (PKCα) signaling pathway as one of their downstream mechanisms. At present, research efforts are mainly focused on the exploration of agents that alter growth factor (such as IGF-1) and cytokine (such as IL-6) signaling for their potential application as therapeutic agents, as both of these have been reported to modulate disease outcome. In the present study, IGF-1 and IL-6 served distinct roles in the androgen responsive LNCaP cell line and in the androgen refractory PC-3 cell line in a dose- and time-dependent manner. Increased phosphorylation of Rictor at the Thr-1135 residue, AKT at the Ser-473 residue and PKCα at the Ser-657 residue were observed after treatment with IGF-1 and IL-6. Subsequently, it was found that diosmetin, a natural plant aglycone, had the potential to modulate the downstream signaling cascade of Rictor/AKT/PKCα to inhibit the progression of prostate cancer. Treatment of LNCaP and PC-3 cells with diosmetin inhibited the phosphorylation of Rictor (Thr-1135), AKT (Ser-473) and PKCα (Ser-657) in a dose-dependent manner. Furthermore, the Bax/Bcl-2 expression ratio was increased in response to diosmetin treatment, which would result in increased apoptosis. Based on these observations, diosmetin may represent a novel therapeutic target for prostate cancer.

Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation Via P53 Activation in Human Renal Carcinoma ACHN Cells

Diosmetin, a Potential P53 Activator, Performs Anticancer Effect by Regulating Cell Cycling and Cell Proliferation in HepG2 Cells.

Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells

Diosmetin induces apoptosis and protective autophagy in human gastric cancer HGC-27 cells via the PI3K/Akt/FoxO1 and MAPK/JNK pathways

Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer

Diosmetin Inhibits Cell Proliferation and Promotes Apoptosis Through STAT3/c-Myc Signaling Pathway in Human Osteosarcoma Cells.

Dioscin Facilitates ROS-induced Apoptosis Via the P38-Mapk/hsp27-mediated Pathways in Lung Squamous Cell Carcinoma

Diosgenin Induces Cell Cycle Arrest and Apoptosis in Human Leukemia K562 Cells with the Disruption of Ca2+ Homeostasis

Anti-Proliferation and Pro-Apoptotic Effects of Diosmetin Via Modulating Cell Cycle Arrest and Mitochondria-Mediated Intrinsic Apoptotic Pathway in MDA-MB-231 Cells

Diosmetin Induces Apoptosis and Enhances the Chemotherapeutic Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells Via Nrf2 Inhibition.

Diosmetin Induces Modulation of Igf-1 and Il-6 Levels to Alter Rictor-Akt-PKCα Cascade in Inhibition of Prostate Cancer

Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by P53-Mediated Downregulation of Survivin.

Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN

Diosmin reduces cell viability of A431 skin cancer cells through apoptotic induction

Radiosensitizing Effect of Diosmetin on Radioresistant Lung Cancer Cells Via Akt Signaling Pathway.

Dioscin induces cancer cell apoptosis through elevated oxidative stress mediated by downregulation of peroxiredoxins.

Diosgenyl Saponin Inducing Endoplasmic Reticulum Stress and Mitochondria-Mediated Apoptotic Pathways in Liver Cancer Cells.

Diosgenin Induces ROS-dependent Autophagy and Cytotoxicity Via Mtor Signaling Pathway in Chronic Myeloid Leukemia Cells

Dioscin Promotes Prostate Cancer Cell Apoptosis and Inhibits Cell Invasion by Increasing SHP1 Phosphorylation and Suppressing the Subsequent MAPK Signaling Pathway

Dioscin Inhibited Glycolysis and Induced Cell Apoptosis in Colorectal Cancer Via Promoting C-Myc Ubiquitination and Subsequent Hexokinase-2 Suppression

Dioscin induced activation of p38 MAPK and JNK via mitochondrial pathway in HL-60 cell line.